In the last trading session, 17.87 million shares of the Novabay Pharmaceuticals Inc (AMEX:NBY) were traded, and its beta was 0.75. Most recently the company’s share price was $0.65, and it changed around $0.1 or 18.24% from the last close, which brings the market valuation of the company to $3.18M. NBY currently trades at a discount to its 52-week high of $12.84, offering almost -1875.38% off that amount. The share price’s 52-week low was $0.36, which indicates that the current value has risen by an impressive 44.62% since then. We note from Novabay Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.9 million shares, with the 3-month average coming to 2.55 million.
Novabay Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended NBY as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Novabay Pharmaceuticals Inc is expected to report earnings per share of -0.3 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novabay Pharmaceuticals Inc (AMEX:NBY) trade information
Instantly NBY has showed a green trend with a performance of 18.24% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.7190 on recent trading dayincreased the stock’s daily price by 9.6%. The company’s shares are currently down -90.89% year-to-date, but still up 10.12% over the last five days. On the other hand, Novabay Pharmaceuticals Inc (AMEX:NBY) is -5.56% down in the 30-day period.
Novabay Pharmaceuticals Inc (NBY) estimates and forecasts
Novabay Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -76.99 percent over the past six months and at a 98.80% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 97.70% in revenue this quarter, and will report an increase of 99.60% in the next quarter. The year-over-year growth rate is expected to be -26.70%, down from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 2.62M in revenue for the current quarter. 2 analysts expect Novabay Pharmaceuticals Inc to make 3.15M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.55M and 3.73M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -26.20%. Forecasts for the next quarter put sales growth at -15.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 24.47%.
NBY Dividends
Novabay Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in November.
Novabay Pharmaceuticals Inc (AMEX:NBY)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.02% of Novabay Pharmaceuticals Inc shares, and 0.24% of them are in the hands of institutional investors. The stock currently has a share float of 0.24%.
